| | 1496581-76-0 Basic information More.. |
| Product Name: | GNE-3511 | | Synonyms: | 2-[[6-(3,3-difluoropyrrolidin-1-yl)-4-[1-(oxetan-3-yl)piperidin-4-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile;2-{[6-(3,3-DIFLUOROPYRROLIDIN-1-YL)-4-[1-(OXETAN-3-YL)PIPERIDIN-4-YL]PYRIDIN-2-YL]AMINO}PYRIDINE-4-CARBONITRILE;CS-2506;GNE3511;GNE 3511;GNE-3511;2-((6-(3,3-DIFLUOROPYRROLIDIN-1-YL)-4-(1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE;4-Pyridinecarbonitrile, 2-[[6-(3,3-difluoro-1-pyrrolidinyl)-4-[1-(3-oxetanyl)-4-piperidinyl]-2-pyridinyl]amino]-;GNE35Chemicalbook11 | | CAS: | 1496581-76-0 | | MF: | C23H26F2N6O | | MW: | 440.49 | | EINECS: | | | Mol File: | 1496581-76-0.mol |  |
Use
GNE-3511 is a selective and highly potent inhibitor of dual leucine zipper kinase (DLK). It also inhibits phosphorylated JNKand is highly selective for DLK over other MAP kinases. In an MPTP mouse model of Parkinsons disease, a high dose of GNE-3511 completely suppresses phosphorylated c-Jun (p-c-Jun) expression, while a low dose moderately reduces its expression. Study has also shown that GNE03511 displayed concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease. These results suggest that GNE-3511 may have therapeutic potential in multiple indications.
- GNE-3511
-
- US $43.00-118.00 / mg
- 2025-04-29
- CAS:1496581-76-0
- Min. Order:
- Purity: 98.64%
- Supply Ability: 10g
|
|
1496581-76-0
Recommend Suppliers |
|